Prosecution Insights

Browse Companies Examiners Firms Draft Your Response

Last updated: August 17, 2026

Examiner: STEVENS, MARK V

Tech Center 1600 • Art Units: 1613 1646 1655

This examiner grants 66% of resolved cases

Performance Statistics

65.5%

Allow Rate

+5.5% vs TC avg

918

Total Applications

+41.9%

Interview Lift

970

Avg Prosecution Days

Based on 860 resolved cases, 2023–2026

Rejection Statute Breakdown

5.0%

§101 Eligibility

11.7%

§102 Novelty

39.8%

§103 Obviousness

23.7%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
18775416	POROUS MEDICAL DEVICE AND METHODS OF USE	Non-Final OA	Boston Scientific Scimed, Inc.
18984644	PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE	Non-Final OA	ANTECIP BIOVENTURES II LLC
18517448	ANTI-TUMOR AGENT	Non-Final OA	FUJIFILM Corporation
18684750	HERBICIDAL MALONAMIDES	Non-Final OA	BASF SE
18572884	COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES	Final Rejection	The Regents of the University of Michigan
18870231	HERBICIDAL DERIVATIVES	Non-Final OA	SYNGENTA CROP PROTECTION AG
18802080	SOLVENT-BASED DETERGENT COMPOSITIONS AND METHODS FOR HYDROPHOBIC SOIL REMOVAL	Non-Final OA	ECOLAB USA INC.
18169695	HEMOSTATIC NANOPARTICLES FOR THE TREATMENT OF NON-COMPRESSIBLE HEMORRHAGE AND INTERNAL BLEEDING	Non-Final OA	The General Hospital Corporation
18928222	INJECTABLE ANTI-HEART FAILURE HYDROGEL WITH MYOCARDIAL TISSUE REPAIR FUNCTION, PREPARATION METHOD AND USE THEREOF	Non-Final OA	SICHUAN UNIVERSITY

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy